objectiveit
therefor
advantag
establish
intracellular
potenc
antivir
drug
candid
earli
drugdiscoveri
pipelin
methodsto
end
cellbas
assay
develop
employ
highthroughput
drug
screen
rang
assay
monitor
replic
intact
virus
monitor
activ
specif
viral
protein
numer
cellbas
assay
develop
investig
rapid
counter
screen
also
need
defin
specif
viral
target
identifi
inhibitor
elimin
nonspecif
screen
hit
resultsconclusionsher
describ
type
cellbas
assay
use
antivir
drug
screen
evalu
equal
import
counter
screen
employ
reach
full
potenti
cellbas
highthroughput
screen
antivir
marketplac
seen
tremend
growth
past
decad
expect
remain
strong
new
viral
target
identifi
continu
problem
viral
resist
present
new
opportun
develop
nextgener
drug
replac
exist
treatment
need
mount
effect
biodefens
highli
pathogen
virus
introduc
emerg
market
sharpli
increas
government
fund
support
develop
effect
therapeut
countermeasur
despit
opportun
pharmaceut
industri
face
spiral
cost
result
part
failur
promis
drug
candid
pass
test
potenc
safeti
human
quest
success
antivir
drug
hamper
fact
success
drug
must
often
enter
infect
cell
neutral
replic
viru
without
caus
harm
host
cell
meet
challeng
drug
screen
evalu
program
incorpor
methodolog
better
predict
lead
compound
respons
human
reason
cellbas
assay
increasingli
devis
use
highthroughput
screen
antivir
chemic
compound
use
intracellular
viral
target
identifi
chemic
inhibitor
compound
potenc
intrins
depend
membran
permeabl
condit
cytotox
relev
assay
paramet
use
cellbas
assay
highthroughput
screen
downstream
test
focus
chemic
compound
exhibit
desir
biolog
properti
cellbas
assay
howev
without
problem
use
highthroughput
screen
cellbas
assay
present
myriad
chemic
reaction
ongo
simultan
viral
activ
interest
due
biolog
complex
cellbas
assay
compound
hit
highthroughput
screen
could
act
nonspecif
alter
cell
abil
host
viral
replic
mainten
compound
could
prove
use
drug
therapi
elucid
mechan
action
add
overal
cost
challeng
face
pharmaceut
industri
therefor
develop
drug
screen
strategi
rapidli
elucid
target
drug
action
context
cellbas
highthroughput
screen
describ
type
cellbas
assay
current
use
screen
antivir
drug
discuss
approach
aid
util
discov
effect
viralspecif
inhibitor
plaqu
reduct
goldstandard
evalu
efficaci
inhibitor
mani
viral
pathogen
assay
labor
intens
plaquereduct
assay
often
use
evalu
candid
inhibitor
alreadi
identifi
mean
fortun
rapid
cytopath
viral
assay
develop
refin
recent
year
highthroughput
drug
screen
three
major
approach
differ
probe
use
assess
virusinduc
cell
degener
neutral
red
cytotox
assay
make
use
vital
dye
neutral
red
ad
cell
diffus
across
plasma
membran
accumul
acid
lysosom
compart
due
mildli
cation
properti
neutral
red
virusinduc
cell
degener
lead
membran
fragment
loss
lysosom
atpdriven
proton
transloc
activ
consequ
reduct
intracellular
neutral
red
assess
spectrophotometr
multiwel
plate
format
neutral
red
assay
adapt
highthroughput
drug
screen
use
identifi
inhibitor
viral
pathogen
score
increas
intracellular
neutral
red
thu
gainofsign
color
assay
second
approach
monitor
viral
cytotox
make
use
tetrazolium
compound
one
compound
inner
salt
mt
commerci
avail
name
celltit
aqueou
one
solut
cell
prolifer
assay
promega
tetrazoliumbas
cytopath
assay
also
avail
variou
supplier
name
xtt
cell
prolifer
kit
colorimetr
method
determin
cell
viabil
reli
enzymat
reduct
tetrazolium
salt
color
formazan
compound
within
cell
candid
antivir
inhibitor
score
spectrophotometr
gain
absorb
readili
monitor
multwel
plate
format
third
recent
approach
monitor
virusinduc
cytotox
make
use
luciferas
enzym
sold
celltiterglo
luminesc
cell
viabil
assay
promega
luciferas
gener
stabl
luminesc
signal
amen
multiwel
plate
format
luciferas
enzym
requir
atp
gener
light
metabol
activ
cell
glow
celltiterglo
assay
signific
advantag
abovement
cytotox
assay
requir
singl
reagent
cell
wash
step
highli
sensit
cytopath
viral
assay
offer
advantag
also
disadvantag
use
highthroughout
drug
screen
import
advantag
use
replic
viru
provid
excel
cell
model
evalu
potenc
drug
candid
anoth
advantag
methodolog
employ
current
cytopath
viral
assay
gainofsign
end
point
identifi
antivir
hit
gainofsign
readout
superior
lossofsign
readout
design
highthroughput
screen
assay
falseposit
hit
interfer
assay
readout
elimin
initi
stage
test
among
falseposit
hit
would
elimin
cytopath
viral
assay
potenti
larg
number
toxic
compound
innat
cellular
degen
properti
live
viru
employ
cytopath
viral
assay
candid
inhibitor
interfer
one
mani
step
viral
life
cycl
identifi
precis
viral
target
add
drugdiscoveri
cost
use
infecti
virus
highthroughput
drug
screen
also
present
uniqu
problem
associ
contain
investig
safeti
instead
use
dye
fluoresc
probe
monitor
cytopath
viral
effect
describ
report
probe
employ
monitor
viral
replic
direct
manner
employ
reporterviru
reportercel
assay
report
viru
assay
report
cell
assay
similar
approach
differ
design
report
viru
assay
report
gene
insert
nonessenti
region
viral
genom
lead
express
correspond
report
protein
viru
replic
insid
cell
use
report
cell
assay
report
gene
insert
target
cell
activ
upon
viral
infect
inhibitor
viral
replic
decreas
reporterprotein
express
thu
activ
report
protein
lossofsign
endpoint
yield
potenti
high
number
falseposit
hit
deriv
molecul
interfer
activ
report
protein
molecul
advers
affect
health
target
cell
thu
abil
host
robust
replic
viru
reason
cytotox
assay
perform
parallel
primari
screen
assist
discoveri
viralspecif
inhibitor
first
demonstr
discoveri
inhibitor
human
immunodefici
viru
hiv
highthroughput
screen
inhibitor
measl
viru
reporterbas
assay
util
live
viru
thu
offer
advantag
present
abovedescrib
cytopath
viral
assay
lossofsign
endpoint
report
viruscel
assay
illustr
need
robust
counter
screen
rapidli
identifi
genuin
antivir
lead
compound
overcom
problem
associ
cultur
live
viru
cell
viral
replicon
assay
establish
employ
subset
viral
gene
specif
requir
replic
viral
genom
good
exampl
viral
replicon
assay
come
studi
hepat
c
viru
hcv
subgenom
hcv
replic
effici
cultur
cell
express
hcv
nonstructur
protein
essenti
hcv
replic
insid
host
cell
luminesc
fluoresc
probe
incorpor
hcv
replicon
enabl
implement
highthroughput
screen
inhibitor
hcv
replic
highthroughput
screen
hit
hcv
replic
score
decreas
luminesc
fluoresc
signal
viral
replicon
assay
similar
design
report
viru
assay
incorpor
luminesc
fluoresc
report
viral
genom
type
assay
suffer
problem
lossofsign
endpoint
use
highthroughput
screen
antivir
drug
counter
screen
therefor
requir
elimin
falseposit
hit
advers
affect
health
cell
thu
abil
host
viral
replic
use
twodimension
display
analysi
screen
hit
hcv
replicon
falseposit
hit
highthroughput
screen
minim
examin
potenc
cell
toxic
simultan
result
display
twodimension
graphic
antivir
activ
plot
cytotox
hcv
inhibitor
minim
cytotox
rapidli
identifi
approach
taken
step
oboyl
et
al
identifi
hcv
replicon
inhibitor
employ
two
simultan
counter
screen
one
cell
toxic
anoth
employ
relat
viral
replicon
bovin
viral
diarrhea
viru
three
screen
perform
tandem
within
multiwel
plate
power
approach
account
potenc
toxic
also
flag
hcvspecif
power
way
elimin
nonspecif
screen
hit
inhibit
product
viral
replicon
innov
modif
improv
reliabl
find
targetspecif
nontox
antivir
earli
stage
drugdiscoveri
pipelin
viral
replicon
assay
make
use
multipl
viral
gene
screen
assay
addit
downstream
effort
need
identifi
specif
viral
target
given
inhibitor
cellbas
assay
also
develop
target
viral
gene
promot
act
specif
step
viral
life
cycl
assay
develop
locu
control
region
human
papillomaviru
drive
express
oncoprotein
cervic
cancer
coreceptorbind
region
howev
major
genetarget
assay
monitor
viral
proteas
cellbas
format
numer
proteasespecif
viral
assay
engin
repres
exampl
discuss
illustr
challeng
develop
highthroughput
assay
resolv
essenti
viral
proteas
serv
frequent
target
inhibitor
screen
cellbas
biochem
assay
inde
inhibitor
proteas
hiv
alreadi
identifi
current
use
patient
express
function
proteas
cell
problemat
due
proteas
suscept
essenti
hostcel
protein
case
proteas
human
immunodefici
viru
hiv
variou
strategi
adopt
overcom
problem
proteas
toxic
includ
transient
transfect
gene
encod
proteas
hela
cell
gene
encod
proteas
introduc
cultur
cell
fusion
gene
encod
green
fluoresc
protein
gfp
proteinfus
joint
contain
proteas
cleavag
site
gfp
releas
intracellularli
fluoresc
signal
suppress
due
cytotox
proteas
except
proteas
inhibitor
ad
cultur
medium
consequ
increas
cellular
fluoresc
use
quantifi
intracellular
potenc
hiv
proteas
inhibitor
cytotox
effect
hiv
proteas
also
seen
varieti
model
cell
exploit
growthbas
assay
hiv
proteas
inhibitor
bacteria
idea
straightforward
plasmid
encod
hiv
proteas
introduc
bacteri
cell
render
dormant
freez
upon
thaw
incub
cell
media
along
screen
compound
inhibitor
hiv
proteas
identifi
cell
growth
gainofsign
endpoint
viral
proteas
cytotox
littl
concern
differ
strategi
develop
use
cellbas
assay
often
involv
yeast
model
eukaryot
cell
mani
wellcharacter
promot
protein
express
common
approach
introduc
viral
proteas
cleavag
site
host
cell
protein
usual
one
produc
condit
growth
defect
upon
inactiv
viral
proteas
viral
inhibitor
growth
select
combinatori
chemic
libari
multiwel
micropl
increas
optic
densiti
screen
viral
inhibitor
growth
select
cost
effect
inexpens
media
use
screen
assay
reli
cell
growth
assay
readout
ensur
identifi
hit
nontox
membran
permeabl
howev
screen
reli
sole
growth
hostcel
could
elimin
desir
inhibitor
toler
level
toxic
word
growthstimulatori
effect
proteas
inhibitor
might
offset
growthinhibitori
effect
mildlytox
compound
anoth
potenti
problem
screen
hit
could
bypass
proteas
stimul
cell
growth
unrel
mean
problem
illustr
need
effect
rapid
counter
screen
elimin
falseposit
hit
research
microbi
novoteq
http
wwwmicrobialnovoteqscom
develop
novel
drug
discoveri
platform
use
engin
yeast
strain
report
action
viral
proteas
cellgrowth
phenotyp
yeast
saccharomyc
cerevisia
engin
yeast
strain
respond
intracellular
viral
proteas
growthdepend
manner
proteas
inhibitor
desir
pharmacolog
properti
includ
membraneperm
nontox
rapidli
econom
identifi
initi
screen
step
establish
assay
fuse
dominantneg
nuclear
protein
npr
dn
membran
anchor
misloc
npr
dn
cytoplasm
compart
posit
endoproteas
cleavag
site
report
membran
anchor
proteas
cleavag
releas
npr
dn
membran
lead
nuclear
transport
fig
express
fusion
substrat
regul
provid
condit
growth
phenotyp
accordingli
inhibitor
proteas
prevent
transport
npr
dn
nucleu
suppress
consequ
conditionalgrowth
defect
permit
identif
proteas
inhibitor
cellgrowth
select
due
modular
natur
assay
cleavag
site
differ
viral
proteas
insert
fusion
substrat
permit
engin
cellbas
assay
varieti
viral
proteas
facet
assay
permit
implement
highthroughput
counter
screen
process
term
multiplex
multiplex
analysi
util
two
proteas
assay
tandem
screen
combinatori
librari
inhibitor
viral
proteas
although
proteas
may
function
structur
distinct
assay
use
monitor
relat
permit
identif
inhibitor
specif
toward
proteas
figur
multiplex
analysi
also
provid
way
identifi
mildli
toxic
viral
inhibitor
might
partial
inhibit
growth
cellbas
assay
show
potenc
toward
particular
proteas
taken
togeth
multiplex
provid
highli
econom
way
employ
two
highthroughput
screen
screen
serv
counter
screen
goal
earlystag
drugdiscoveri
program
develop
methodolog
best
predict
drug
perform
human
mani
instanc
success
antivir
drug
must
cross
cell
membran
inhibit
viral
life
cycl
without
caus
harm
host
cell
end
varieti
cellbas
assay
develop
use
antivir
highthroughput
screen
type
assay
current
oper
rang
cellbas
assay
monitor
replic
intact
viru
monitor
activ
singl
viral
protein
replic
intact
virus
assess
use
cytopath
viral
assay
report
viru
assay
report
cell
assay
among
three
cytopath
viral
assay
offer
signific
advantag
gainofsign
endpoint
inhibitor
viral
activ
gainofsign
assay
desir
highthroughput
drug
screen
order
minim
falseposit
screen
hit
eg
hit
interfer
assay
readout
effici
counter
screen
essenti
lossofsign
assay
use
highthroughput
screen
cytotox
counter
screen
success
employ
report
viru
assay
report
cell
assay
elimin
falseposit
hit
inhibit
cell
viabil
thu
cell
abil
host
viral
replic
case
replic
intact
viru
difficult
achiev
cell
cultur
case
hcv
viral
replicon
subgenom
portion
viral
genom
engin
express
report
protein
concomit
replicon
although
viral
replicon
assay
reli
lossofsign
endpoint
inhibitor
viral
replic
success
employ
highthroughput
drug
screen
attribut
part
develop
innov
highthroughput
counter
screen
one
inhibitor
toxic
anoth
use
relat
viral
replicon
inhibitor
hcv
replic
thu
simultan
evalu
cytotox
hcv
specif
approach
term
multiplex
drugscreen
effort
microbi
novoteq
cellbas
assay
also
develop
monitor
specif
viral
protein
manner
suitabl
highthroughput
drug
screen
use
approach
viral
gene
promot
express
insid
model
cell
activ
viral
genepromot
monitor
variou
mean
hiv
proteas
provid
exampl
viral
protein
inhibit
hostcel
growth
due
broad
substrat
specif
monitor
cell
growth
gainofsign
readout
cellbas
assay
use
highthroughput
screen
hiv
proteas
inhibitor
mani
viral
proteas
exhibit
limit
specif
toward
host
cell
target
instead
cognat
viral
cleavag
site
proteas
express
propag
cell
consequ
cellbas
assay
use
monitor
nontox
viral
proteas
reli
engin
substrat
provid
condit
growth
phenotyp
identifi
proteas
inhibitor
primari
advantag
monitor
specif
viral
genepromot
highthroughput
drug
screen
identifi
inhibitor
expect
target
defin
viral
activ
howev
reach
full
potenti
cellbas
assay
viralspecif
gene
highthroughput
counter
screen
need
context
cellbas
assay
avail
biochem
assay
viral
protein
use
counter
screen
biochem
assay
typic
expens
perform
cellbas
assay
due
requir
purifi
protein
often
fluorescentlylabel
substrat
cellbas
counter
screen
employ
confirm
specif
highthroughput
screen
hit
sum
varieti
power
innov
cellbas
assay
develop
use
highthroughput
screen
antivir
drug
candid
cellbas
assay
provid
mean
screen
potent
viral
inhibitor
intracellular
platform
use
drug
discoveri
program
permit
identif
drug
candid
desir
pharmacolog
properti
earli
drugdiscoveri
pipelin
cellbas
assay
innat
complex
larg
number
nonspecif
falseposit
screen
hit
like
aris
highthroughput
screen
drugdiscoveri
field
appropri
focus
develop
new
power
primari
drug
screen
equal
import
focu
futur
research
need
center
around
develop
rapid
econom
counter
screen
thu
permit
identif
highli
specif
viral
inhibitor
rapid
econom
manner
duplex
analysi
chemic
inhibitor
proteas
produc
hepat
viru
norwalk
viru
depict
repres
duplex
analysi
compound
test
potenc
hepat
viru
hav
norwalk
viru
gray
dot
coordin
repres
averag
growth
yeast
yaxi
vs
yeast
xaxi
presenc
particular
test
compound
rel
neg
control
compound
repres
quadrant
activ
assay
deem
nonspecif
likewis
appear
quadrant
iii
inhibit
assay
thu
judg
toxic
interest
compound
appear
quadrant
ii
iv
quadrant
ii
compound
activ
hav
assay
show
neglig
slightli
toxic
effect
norwalk
assay
therefor
like
specif
hav
inhibitor
revers
true
quadrant
iv
repres
compound
specif
norwalk
inhibitor
